Latest filing published 12 Aug 2026 for Treace Medical Concepts, INC..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Sean F. Scanlan, listed as senior executive, appears in our data through filings on Treace Medical Concepts, Inc. shares, published by SEC (Form 4). The record holds 54 filings, for trades running from 10 November 2021 to 9 August 2026.
No open-market purchase appears, only 16 sales worth €4.9M. The rest of the record consists of 18 share grants and 20 option exercises.
On 12 August 2026 came the latest disclosure, a share grant in Treace Medical Concepts, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 28 declarations